FLT3 and acute myeloid leukemia: In a phase III trial, 202 patients with FLT3-ITD-mutated AML undergoing allo-HCT were randomized to maintenance therapy with either sorafenib 400 mg BID (n = 100) or placebo (n = 102) [27] for up to 6 months post-transplant.